CVMライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	136 601
平均出来高	308 612
時価総額	77.73M
EPS	$0 ( 2024-02-13 )
次の収益日	( $-0.140 ) 2024-05-10
Last Dividend	$0.250 ( 1996-08-28 )
Next Dividend	$0 ( N/A )
P/E	-2.09
ATR14	$0.00700 (0.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Gobbo Mario	Sell	0	Common Stock
2024-04-19	Gobbo Mario	Sell	64 000	Options
2024-04-19	Watson Robert Eugene	Buy	64 000	Options
2024-04-19	Baillavoine Bruno Jean-marie	Buy	64 000	Options
2024-04-19	Talor Eyal	Buy	182 000	Options

INSIDER POWER
90.73
Last 100 transactions
Buy: 5 618 116 \| Sell: 153 000

ボリューム相関

長: -0.23 (neutral)

短: -0.13 (neutral)

Signal:(41.527) Neutral

CEL-SCI Corp 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

CEL-SCI Corp 相関 - 通貨/商品

-0.65
( moderate negative )

-0.63
( weak negative )

0.00
( neutral )

-0.57
( weak negative )

0.00
( neutral )

0.47
( neutral )

CEL-SCI Corp 財務諸表

Annual	2023
収益:	$0
総利益:	$-3.96M (0.00 %)
EPS:	$-0.720

FY	2023
収益:	$0
総利益:	$-3.96M (0.00 %)
EPS:	$-0.720

FY	2022
収益:	$0
総利益:	$-3.88M (0.00 %)
EPS:	$-0.890

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.900

Financial Reports:

No articles found.

CEL-SCI Corp Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

CEL-SCI Corp Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.250	1996-08-28
Last Dividend	$0.250	1996-08-28
Next Dividend	$0	N/A
Payout Date	2017-06-15
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.250	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for AMEX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
EVV	Ex Dividend King	2023-09-08	Monthly	0.00%
NBH	Ex Dividend Knight	2023-09-28	Monthly	0.00%
UTG	Ex Dividend Knight	2023-08-17	Monthly	0.00%
BOAT	Ex Dividend Junior	2023-06-27	Quarterly	0.00%
ENX	Ex Dividend King	2023-09-21	Monthly	0.00%
KDRN	Ex Dividend Junior	2023-06-26	Quarterly	0.00%
SCCB	Ex Dividend Knight	2023-09-14	Quarterly	0.00%
AIVL	Ex Dividend Junior	2023-06-26	Bi-Monthly	0.00%
IHT	Ex Dividend Knight	2023-07-19	Semi-Annually	0.00%
PRK	Ex Dividend Knight	2023-08-17	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-1.087	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-2.05	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.264	0.800	8.68	6.94	[1 - 3]
quickRatioTTM	0.184	0.800	-3.62	-2.90	[0.8 - 2.5]
cashRatioTTM	0.666	1.500	7.41	10.00	[0.2 - 2]
debtRatioTTM	0.456	-1.500	2.40	-3.59	[0 - 0.6]
interestCoverageTTM	-42.08	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.476	2.00	-0.159	-0.317	[0 - 30]
freeCashFlowPerShareTTM	-0.484	2.00	-0.242	-0.484	[0 - 20]
debtEquityRatioTTM	1.035	-1.500	5.86	-8.79	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-1.761	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-2.64

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.24	1.000	-0.327	0	[1 - 100]
returnOnEquityTTM	-2.05	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.484	2.00	-0.161	-0.484	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.476	2.00	-0.159	-0.317	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0447	1.500	-3.63	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-1.891

CEL-SCI Corp

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.